Verastem Inc (VSTM)

$7.32 -0.30 (-3.94%)
Market Cap 662.92M
Revenue (ttm) 30.91M
Net Income (ttm) -209.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -677.68%
Debt to Equity Ratio 1.48
Volume 1,913,800
Avg Vol 2,310,740
Day's Range N/A - N/A
Shares Out 90.56M
Stochastic %K 21%
Beta 0.32
Analysts Strong Sell
Price Target $15.00

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small mole...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
LabPsycho
LabPsycho Sep. 13 at 6:03 PM
$VSTM @CrozrX The first page is a an impressive A.I. rendering. If only they would have included one of the atomically accurate structures from my recent molecular dynamic simulations posted below and on Youtube.
0 · Reply
sweddle
sweddle Sep. 13 at 3:13 PM
$VSTM
0 · Reply
JFais
JFais Sep. 12 at 7:50 PM
$VSTM at Cantor: "We're seeing some really exciting data when combining with cetuximab in pancreatic as well as CRC" -Potential partners have access to the data in real time, hope to secure a large deal to protect upside but fund trials in non-dilutive way -Oberland deal takes the pressure off having to decide today
0 · Reply
CrozrX
CrozrX Sep. 12 at 2:35 PM
$VSTM https://finance.biggo.com/news/cef6b5f4f91d305e
2 · Reply
Timster23
Timster23 Sep. 11 at 10:35 PM
$VSTM Not a real good day for a bunch of bios
0 · Reply
DrTim
DrTim Sep. 11 at 7:14 PM
$VSTM Purely speculation but if VSTM gets accelerated approval for LGSOC WT, what would we anticipate the stock price increasing to? 
1 · Reply
Mattyk7
Mattyk7 Sep. 11 at 4:43 PM
$VSTM Great time to add, just bought 10,000 more shs. Better than Vegas!
0 · Reply
sweddle
sweddle Sep. 11 at 4:29 PM
$VSTM
0 · Reply
sweddle
sweddle Sep. 11 at 3:44 PM
$VSTM
0 · Reply
PencilNeckGeek
PencilNeckGeek Sep. 11 at 2:12 PM
$VSTM Looking pretty weak again. Hopefully it at least holds in the $7.50 range
1 · Reply
Latest News on VSTM
Verastem Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2026, 8:35 AM EDT - 3 days ago

Verastem Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Verastem to unveil new clinical data on VS-7375

2026-09-08T11:40:26.000Z - 5 days ago

Verastem to unveil new clinical data on VS-7375

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Sep 8, 2026, 7:30 AM EDT - 5 days ago

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Verastem Oncology to Participate in Upcoming September Investor Conferences

Sep 2, 2026, 7:30 AM EDT - 11 days ago

Verastem Oncology to Participate in Upcoming September Investor Conferences

Verastem price target lowered to $13 from $14 at Mizuho

2026-08-11T11:32:36.000Z - 4 weeks ago

Verastem price target lowered to $13 from $14 at Mizuho

Verastem price target lowered to $13 from $14 at Mizuho

2026-08-10T17:00:09.000Z - 4 weeks ago

Verastem price target lowered to $13 from $14 at Mizuho

Verastem price target lowered to $12 from $14 at Guggenheim

2026-08-07T11:36:06.000Z - 5 weeks ago

Verastem price target lowered to $12 from $14 at Guggenheim

Verastem Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Verastem Earnings Call Transcript: Q2 2026

Verastem Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Verastem Earnings release: Q2 2026

Verastem Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Verastem Quarterly report: Q2 2026

Verastem Slides: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Verastem Slides: Q2 2026

Verastem reports Q2 adjusted EPS (31c), consensus (44c)

2026-08-06T20:06:55.000Z - 5 weeks ago

Verastem reports Q2 adjusted EPS (31c), consensus (44c)

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Aug 6, 2026, 4:01 PM EDT - 5 weeks ago

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Slides: Corporate presentation

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

Verastem Slides: Corporate presentation

Verastem doses first patients in Target-D 203 Phase 2 trial

2026-07-28T20:05:22.000Z - 6 weeks ago

Verastem doses first patients in Target-D 203 Phase 2 trial

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Jul 28, 2026, 4:01 PM EDT - 6 weeks ago

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 23, 2026, 7:30 AM EDT - 7 weeks ago

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Verastem doses first patient in TARGET-D 202 Phase 2 trial

2026-07-22T20:06:33.000Z - 7 weeks ago

Verastem doses first patient in TARGET-D 202 Phase 2 trial

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Jul 22, 2026, 4:01 PM EDT - 7 weeks ago

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Verastem price target lowered to $14 from $15 at RBC Capital

2026-07-07T11:35:39.000Z - 2 months ago

Verastem price target lowered to $14 from $15 at RBC Capital

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2026, 4:30 PM EDT - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Transcript: Study update

Jun 23, 2026, 4:30 PM EDT - 2 months ago

Verastem Transcript: Study update

Verastem Press release: Study update

Jun 23, 2026, 4:30 PM EDT - 2 months ago

Verastem Press release: Study update

Verastem Slides: Study update

Jun 23, 2026, 4:30 PM EDT - 2 months ago

Verastem Slides: Study update

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

2026-06-23T20:08:14.000Z - 2 months ago

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Jun 23, 2026, 4:01 PM EDT - 2 months ago

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

VS

Verastem price target lowered to $8 from $15 at Jefferies

2026-06-23T17:03:54.000Z - 2 months ago

Verastem price target lowered to $8 from $15 at Jefferies

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

2026-06-17T11:36:43.000Z - 2 months ago

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Jun 17, 2026, 7:30 AM EDT - 2 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

2026-06-16T20:07:47.000Z - 2 months ago

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Jun 16, 2026, 4:01 PM EDT - 2 months ago

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Jun 15, 2026, 4:01 PM EDT - 2 months ago

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375

2026-06-03T20:23:19.000Z - 3 months ago

Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375

Verastem announces FDA Fast Track designation for VS-7375

2026-06-03T20:06:01.000Z - 3 months ago

Verastem announces FDA Fast Track designation for VS-7375

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Jun 3, 2026, 4:01 PM EDT - 3 months ago

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Verastem Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:20 AM EDT - 3 months ago

Verastem Transcript: Jefferies Global Healthcare Conference 2026

Verastem Oncology to Present at Jefferies Healthcare Conference

May 27, 2026, 7:30 AM EDT - 3 months ago

Verastem Oncology to Present at Jefferies Healthcare Conference

Verastem appoints Michael Bailey to board of directors

2026-05-26T12:54:22.000Z - 3 months ago

Verastem appoints Michael Bailey to board of directors

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

May 26, 2026, 7:30 AM EDT - 3 months ago

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 9:30 AM EDT - 3 months ago

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026

Verastem Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 4:00 PM EDT - 3 months ago

Verastem Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Verastem price target lowered to $14 from $16 at Mizuho

2026-05-14T12:35:05.000Z - 4 months ago

Verastem price target lowered to $14 from $16 at Mizuho

Verastem Oncology to Present at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 4 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem price target lowered to $18 from $19 at BTIG

2026-05-08T12:55:59.000Z - 4 months ago

Verastem price target lowered to $18 from $19 at BTIG

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

May 8, 2026, 7:30 AM EDT - 4 months ago

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Verastem Earnings Call Transcript: Q1 2026

Verastem Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Verastem Earnings release: Q1 2026

Verastem Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Verastem Quarterly report: Q1 2026

Verastem Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Verastem Slides: Q1 2026

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 7, 2026, 4:01 PM EDT - 4 months ago

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Apr 30, 2026, 7:30 AM EDT - 4 months ago

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 23, 2026, 7:30 AM EDT - 4 months ago

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Apr 10, 2026, 7:00 AM EDT - 5 months ago

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Verastem Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Verastem Proxy statement: Proxy filing

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 6:03 PM EDT - 5 months ago

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Mar 17, 2026, 4:44 PM EDT - 5 months ago

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Verastem Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Earnings Call Transcript: Q4 2025

Verastem Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Earnings release: Q4 2025

Verastem Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Annual report: Q4 2025

Verastem Slides: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Slides: Q4 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Mar 4, 2026, 4:01 PM EST - 6 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Feb 18, 2026, 7:30 AM EST - 6 months ago

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Verastem Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 2:00 PM EST - 7 months ago

Verastem Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Feb 4, 2026, 7:30 AM EST - 7 months ago

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 29, 2025, 4:01 PM EST - 8 months ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Dec 15, 2025, 4:01 PM EST - 9 months ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Verastem Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:25 AM EST - 9 months ago

Verastem Transcript: Evercore ISI 8th Annual HealthCONx Conference

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Verastem Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:30 AM EST - 9 months ago

Verastem Transcript: Jefferies London Healthcare Conference 2025

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 14, 2025, 12:41 AM EST - 10 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 13, 2025, 4:07 PM EST - 10 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Verastem Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 1:00 PM EST - 10 months ago

Verastem Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Verastem Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Verastem Earnings Call Transcript: Q3 2025

Verastem Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Verastem Quarterly report: Q3 2025

Verastem Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Verastem Earnings release: Q3 2025

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov 4, 2025, 7:30 AM EST - 10 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 4:01 PM EDT - 10 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Oct 19, 2025, 4:15 AM EDT - 10 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Verastem Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 1 year ago

Verastem Transcript: Cantor Global Healthcare Conference 2025

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 13, 2025, 4:29 PM EDT - 1 year ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing

Verastem Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing

Verastem Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Verastem Earnings Call Transcript: Q2 2025

Verastem Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Verastem Earnings release: Q2 2025

Verastem Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Verastem Quarterly report: Q2 2025

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 1 year ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 24, 2025, 7:30 AM EDT - 1 year ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jul 11, 2025, 4:12 PM EDT - 1 year ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 30, 2025, 4:02 PM EDT - 1 year ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 24, 2025, 4:02 PM EDT - 1 year ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Verastem Transcript: Jefferies Global Healthcare Conference 2025

Verastem Transcript: R&D Day 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: R&D Day 2025

Verastem Slides: FY 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Slides: FY 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Jun 2, 2025, 9:40 AM EDT - 1 year ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 1 year ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22, 2025, 5:01 PM EDT - 1 year ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:35 PM EDT - 1 year ago

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2025

Verastem Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20, 2025, 8:30 AM EDT - 1 year ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025, 4:34 PM EDT - 1 year ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Registration statement: Registration Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing

Verastem Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Verastem Earnings release: Q1 2025

Verastem Quarterly report: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Verastem Quarterly report: Q1 2025

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 1:17 PM EDT - 1 year ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 1 year ago

U.S. FDA approves Verastem's cancer therapy

Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

LabPsycho
LabPsycho Sep. 13 at 6:03 PM
$VSTM @CrozrX The first page is a an impressive A.I. rendering. If only they would have included one of the atomically accurate structures from my recent molecular dynamic simulations posted below and on Youtube.
0 · Reply
sweddle
sweddle Sep. 13 at 3:13 PM
$VSTM
0 · Reply
JFais
JFais Sep. 12 at 7:50 PM
$VSTM at Cantor: "We're seeing some really exciting data when combining with cetuximab in pancreatic as well as CRC" -Potential partners have access to the data in real time, hope to secure a large deal to protect upside but fund trials in non-dilutive way -Oberland deal takes the pressure off having to decide today
0 · Reply
CrozrX
CrozrX Sep. 12 at 2:35 PM
$VSTM https://finance.biggo.com/news/cef6b5f4f91d305e
2 · Reply
Timster23
Timster23 Sep. 11 at 10:35 PM
$VSTM Not a real good day for a bunch of bios
0 · Reply
DrTim
DrTim Sep. 11 at 7:14 PM
$VSTM Purely speculation but if VSTM gets accelerated approval for LGSOC WT, what would we anticipate the stock price increasing to? 
1 · Reply
Mattyk7
Mattyk7 Sep. 11 at 4:43 PM
$VSTM Great time to add, just bought 10,000 more shs. Better than Vegas!
0 · Reply
sweddle
sweddle Sep. 11 at 4:29 PM
$VSTM
0 · Reply
sweddle
sweddle Sep. 11 at 3:44 PM
$VSTM
0 · Reply
PencilNeckGeek
PencilNeckGeek Sep. 11 at 2:12 PM
$VSTM Looking pretty weak again. Hopefully it at least holds in the $7.50 range
1 · Reply
CrozrX
CrozrX Sep. 11 at 1:58 PM
$VSTM Along KRAS mutated LGSOC responses, Notable KRAS WT responses as well, disease control in RAMP201J. Definitely SOC, time the only factor to implement!
1 · Reply
CrozrX
CrozrX Sep. 11 at 1:54 PM
$VSTM LGSOC RAMP201 vs. Conventional Care 📎 https://cslide.ctimeetingtech.com/igcs26/attendee/confcal/show/session/106
0 · Reply
manny11419
manny11419 Sep. 11 at 11:16 AM
$VSTM One of the reason why VSTM has explosive upside is that the P2's may lead directly to approval...meaning the agents can be on the market by end of 27. This was confirmed at the CF meeting. They're going after AA, BTD's. I suspected thats one of the reasons for the delayed partnership. Good data on OCT.14...and I'll say done deal.
2 · Reply
jacksparo
jacksparo Sep. 11 at 1:58 AM
$SLS $VSTM $CADL $FATE $CABA Some big retreats in some biotech and some mildly affected by the current market dilemma. I think 🤔 at the end mix of patience and being prepared strategy will still do good . August CPI tomorrow at 08:30 AM ET US might be most important individual for the incoming Fed policy announcements. I am preparing my plans and getting ready for all possible scenarios.. Stay positive and focused ✅📈✅📈!
1 · Reply
Always_neutral
Always_neutral Sep. 10 at 10:43 PM
$VSTM Looking forward to the Sunday presentation by GENFLEET. This will be my signal and will load next week if the uninformed shorts keep shorting. Market will be crazy for the next few weeks but this is a good opportunity to load, not there yet. Good luck.
2 · Reply
sweddle
sweddle Sep. 10 at 7:33 PM
$VSTM
0 · Reply
Universaal
Universaal Sep. 10 at 7:17 PM
$VSTM told you all to sell $XERS two days ago $PSNL
0 · Reply
DrTim
DrTim Sep. 10 at 6:54 PM
$VSTM Some on here are angry with the shorts! I say bring them on....the more the merrier. As a long time shareholder, my downside (bought at $3.86) is very limited because of the LGSOC franchise. However, you shorts are going to be in a world of hurt if VSTM announces a partnership and/or accelerated approval for pancreatic cancer! If that day arrives, the volume is going to be in the tens of millions.
1 · Reply
Alt_Fuel
Alt_Fuel Sep. 10 at 3:06 PM
$VSTM $RVMD Revolution Medicine & Verastem latest insights ... TRANSCRIPT - Verastem at Cantor conference: dual-track growth, big bets Transcripts Published Sep 10, 2026, 09:23 AM Key Takeaways - - Verastem said its commercial CO-PACK launch is improving, with better patient acquisition and retention after changes made following the first quarter. - The company’s G12D inhibitor has treated more than 200 patients in Verastem studies and more than 300 additional patients through partner GenFleet in China. - Management said the drug’s dual on/off design, long target residence time and strong selectivity may give it an edge over competing KRAS programs. - Verastem expects a major data presentation on October 14 and plans FDA discussions on Phase III designs in 2024. - The Oberland deal gave the company more financial flexibility as it pursues partnerships and future trials. https://www.investing.com/news/transcripts/verastem-at-cantor-conference-dualtrack-growth-big-bets-93CH-4896091
0 · Reply
sweddle
sweddle Sep. 10 at 1:55 PM
$VSTM
0 · Reply
Alt_Fuel
Alt_Fuel Sep. 10 at 1:32 PM
$VSTM $RVMD both Verastem & Revolution Medicine mentioned ... https://investor.verastem.com/events/event-details/cantor-global-healthcare-conference Title Cantor Global Healthcare Conference Date / Time Sep 10, 2026 at 8:35 AM EDT Cantor Global Healthcare Conference Webcast Presentation LINK - to Listen to webcast https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=59082603&checkCompany=1&checkEmail=1&checkName=1
0 · Reply
sweddle
sweddle Sep. 10 at 1:12 PM
$VSTM good call this morning. Suggest giving a listen. Nothing crazy was said but the tone is the indicator IMHO.
1 · Reply